A mechanistic pharmacokinetic model for liver transporter substrates under liver cirrhosis conditions

Rui Li[1*], Hugh A. Barton[2], and Tristan S. Maurer[1]

Systems Modeling and Simulation, Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide R&D, [1]Cambridge, MA, and [2]Groton, CT.

* Corresponding author

Email address: Rui.Li5@pfizer.com

Telephone number: +1 617 551 3340

Fax number: +1 860 686 5665

Number of references: 40

Number of figures: 3

Number of tables: 4

Key words: liver cirrhosis, liver transporter, PBPK modeling

ABSTRACT

Liver cirrhosis is a disease characterized by the loss of functional liver mass. Physiologically-based pharmacokinetic (PBPK) modeling has been applied to interpret and predict how the interplay among physiological changes in cirrhosis affects pharmacokinetics. However, previous PBPK models under cirrhotic conditions were developed for permeable cytochrome P450 substrates and do not directly apply to substrates of liver transporters. This study characterizes a PBPK model for liver transporter substrates in relation to the severity of liver cirrhosis. A published PBPK model structure for liver transporter substrates under healthy conditions and the physiological changes ~~reported~~ for cirrhosis are combined to simulate pharmacokinetics of liver transporter substrates in patients with mild and moderate cirrhosis. The simulated pharmacokinetics under liver cirrhosis reasonably approximate observations. ~~The major contributions~~ This analysis includes ~~the~~ meta-analysis to obtain system-dependent parameters in cirrhotic patients~~,~~ and a top-down approach to improve understanding of effect of cirrhosis on transporter-mediated drug disposition under cirrhotic conditions.~~This work can be useful in understanding the change of liver transporter activity due to cirrhosis, and predicting pharmacokinetics of liver transporter substrates under cirrhotic conditions.~~

INTRODUCTION

Liver cirrhosis is a progressive disease characterized by loss of liver function associated with the morphological and physiological changes. The disease progression is usually classified using the Child-Pugh Grades (CP-A (mild), CP-B (moderate), and CP-C (severe)) (1). Physiological changes ~~under pathological condition~~ include loss of functional liver size, decreased cytochrome P450 (CYP) expression, reduced glomerular filtration rate (GFR), and altered cardiac output, hepatic blood flow, hematocrit, and plasma albumin and α_1-acid glycoprotein concentrations (1, 2). The changes may affect systematic and tissue exposure of drugs administered to the patient. Under these pathological conditions, it is necessary to assess drug pharmacokinetics to evaluate potential risk and altered pharmacodynamic effects.

Compared with empirical pharmacokinetic models, ~~physiologically~~ physiologically-based pharmacokinetic (PBPK) modeling explicitly incorporates physiological information, and can deconvolute multiple mechanisms controlling drug pharmacokinetics (3). As such, PBPK analysis can be invaluable to gain insights into the impact of physiological changes on the pharmacokinetics under disease conditions. PBPK models have been reported in previous publications to predict the pharmacokinetics in patients with liver impairment (4-6). With a "well-stirred" liver model (7), these PBPK models successfully extrapolate pharmacokinetics from healthy individual to patients, in terms of adequately describing the observed plasma pharmacokinetics under different disease conditions.

In addition to the lipophilic compounds that have been mechanistically modeled (4-6), several groups ~~also~~ have investigated the pharmacokinetics of liver transporter substrates under mild and moderate liver cirrhosis conditions, prompted by the fact that these compounds are mainly

3

eliminated hepatically (8-12). In addition, some liver transporter substrates are developed to treat diseases associated with liver cirrhosis. For example, bosentan (13) is a dual endothelin receptor antagonist used in the treatment of pulmonary artery hypertension, which has a higher prevalence in more severely cirrhotic patients (14). Repaglinide treats type 2 diabetes (15). In a population-based diabetes study, cirrhosis was the fourth leading cause of death and accounted for 4.4% of diabetes-related deaths; diabetes is also the most common cause of liver disease in the U.S. (16). To date, these compounds have not been modeled under cirrhotic conditions using a PBPK approach, and models for highly permeable compounds cannot be reasonably expected to describe the pharmacokinetics of liver transporter substrates (17).

PBPK models for liver transporter substrates have been developed previously, where the distribution of the compounds is modeled as permeability limited in order to incorporate both passive diffusion and active uptake due to transporter activity (18-21). In this study, we extended published PBPK models (18-21) to extrapolate pharmacokinetics from healthy individuals to patients with cirrhosis. The model structure for liver transporter substrate disposition in healthy individuals was combined with adjustments of physiologic parameters reported in the models for high permeable compounds under cirrhotic conditions. This work ~~provides a~~ updates current understanding of the effect of liver cirrhosis on system parameters, including transporter processes, and has potential usefulness in the individualized dosage adjustment of ~~practical approach to predict systemic and potentially liver exposure of the~~ liver transporter substrates under disease conditions.

METHODS

Model structure

The published PBPK model structure for organic anion transporting polypeptides (OATP) substrates incorporating hepatic uptake clearance (CL_{act}), passive diffusion (CL_{pass}), metabolic (CL_{met}), and biliary (CL_{bile}) clearances (19) is applied for bosentan, olmesartan, repaglinide, and valsartan. The model assumes no active basolateral efflux due to challenges of estimating this activity, although it has been described for at least rosuvastatin (22, 23). Enterohepatic recirculation of the parent compound is not modeled for olmesartan and valsartan due to its limited impact on the plasma pharmacokinetic simulations performed with current model (data not shown). For telmisartan, additional model components for deconjugation of glucuronide metabolite and enterohepatic recirculation of parent were added to the PBPK model to account for the long half-life and large apparent volume of distribution observed in clinical data as described before (24).

First order absorption kinetics with absorption rate (k_a), fraction absorbed (F_a) and assuming no intestinal metabolism or transport (i.e., $F_g = 1$) are used to describe plasma data after oral dosing of repaglinide and telmisartan (24). Because the first order absorption cannot adequately describe the plasma concentration-time curves after oral dosing of bosentan and valsartan, a saturable absorption model with maximum absorption rate (V_{max}), and Michaelis–Menten saturation constant (K_m) (25) is used for these two compounds (other empirical absorption models described in (25) including zero-order model, sequential independent zero and first order model, sequential linked zero and first order model, and model with delayed absorption were also tested, but these model did not improve the fitting).

5

The model is implemented in MATLAB (version 2010b). The fitted parameters are estimated by minimizing the squared error between log10 transformed data and simulations, using the pattern search optimizer in the MATLAB Global Optimization Toolbox.

Local sensitivity analysis

Local sensitivity analyses of the area under curve ($AUC_{plasma, 0-t}$ and $AUC_{liver, 0-t}$) are conducted as described previously where each parameter (for healthy individual) is raised by 1% with respect to its value in the simulations (18). Sensitivity coefficients are normalized to both the parameter value and the model output. To keep the blood flow balanced, when the blood flow to any other organ is increased, the lung blood flow and the cardiac output will be raised accordingly. Similarly, if the lung blood flow or the cardiac output is raised, blood flow in all other organs will be increased. If liver arterial blood, gut blood, or spleen blood flow is raised, both lung blood flow and liver venous blood flow will be increased, and *vice versa*. To analyze the sensitivity to the liver mass (for healthy individual the functional liver mass is the same as the physical liver mass), CL_{pass}, CL_{act}, CL_{met}, and CL_{bile} are raised 1% together with the liver volume. Only parameters with normalized sensitivity coefficients greater than 0.3 or less than −0.3 are reported.

Physiological parameters for cirrhosis

Parameters

6

Meta-analysis. We used the same source literature reporting changes for physiological parameter values as published before (5). For the functional liver size analysis, only datasets classified using Pugh-Child system are selected. Studies using functional assays (e.g. galactose elimination capacity or hepatic sorbitol clearance), are not included because the data may be confounded by blood flow, or the expression level of metabolic enzymes. The physiological changes associated with liver cirrhosis are represented as the ratios of mean reported values between the disease group and healthy group (except for $R_{B/P}$). To estimate the population mean of the ratios based on the individual studies, one could pool the measured physiological parameter values, and take the ratios between population means of healthy and cirrhosis groups. However, the measurement techniques for these parameters are different from study to study, as such it may not be proper to pool these measurements directly. To bypass this challenge, instead of pooling the measurements, we take the ratios of individually reported values, and pool the ratios to estimate the population mean of the ratios.

The ratios are calculated as

$$R_i = \frac{x_{cirrohsis,i}}{x_{healthy,i}} \tag{1}$$

where $x_{cirrohsis}$ and $x_{healthy}$ represent the reported sample mean values for cirrhosis group and healthy group in the study i. The standard error (SE) of the ratios in each individual study is calculated through the propagation of uncertainty:

$$SE_i^2 = \left[\frac{x_{cirrohsis,i}}{x_{healthy,i}}\right]^2 \cdot \left[\left[\frac{SE_{cirrhosis,i}}{x_{cirrohsis,i}}\right]^2 + \left[\frac{SE_{healthy,i}}{x_{healthy,i}}\right]^2\right] \tag{2}$$

The sample standard deviations of the ratios (SD_i) are calculated using the same approach. The population mean value (WX) and population standard deviations (SD) of ratios from N individual studies are estimated as follows using the reciprocal of standard error-weighted mean (26) and pooled variance (27).

$$WX = \frac{\sum_{i=1}^{N} \frac{1}{SE_i^2} \cdot R_i}{\sum_{i=1}^{N} \frac{1}{SE_i^2}} \tag{3}$$

$$SD^2 = \frac{\sum_{i=1}^{N} \left((n_i - 1) \cdot SD_i^2 \right)}{\sum_{i=1}^{N} (n_i - 1)} \tag{4}$$

where n_i typically indicates the sample size in the study i. In the clinical studies, n_i was reported for the participants in the healthy and the cirrhotic groups. However, in our analysis which relies on ratios, we approximated n_i as the average number of healthy and cirrhotic participants in each study.

Plasma fraction unbound. Plasma fraction unbound ($f_{u,p}$) of bosentan, repaglinide, telmisartan, and valsartan have been reported for healthy individuals (18, 24). The in-house value of $f_{u,p}$ for olmesartan is used. Assuming the unbound albumin concentration ($C_{albumin}$) is approximately equal to the total albumin concentration (Table 3), $f_{u,p}$ values for patients with liver cirrhosis are estimated based on a previously published approach (28).

$$f_{u,p,cirrhosis} = \frac{1}{\left[\frac{1}{f_{u,p,healthy}} - 1 \right] \cdot \frac{C_{albumin,cirrhosis}}{C_{albumin,heathy}} + 1} \tag{5}$$

Blood to plasma ratio. Blood to plasma ratio ($R_{B/P}$) is defined as

$$R_{B/P} = \frac{C_B}{C_P}$$

$$= \frac{C_E \cdot V_E + C_P \cdot V_P}{V_B} \cdot \frac{1}{C_P}$$

$$= \frac{C_E \cdot HCT \cdot V_B + C_P \cdot (1 - HCT) \cdot V_B}{V_B \cdot C_P} \tag{6}$$

$$= \frac{C_E}{C_P} \cdot HCT + 1 - HCT$$

where C and V represent concentration and volume; B, E, and P represent blood, erythrocyte, and plasma; and HCT represents hematocrit (Table 3). The reported $R_{B/P}$ values for bosentan, repaglinide, and valsartan in healthy individuals are 0.48, 0.48, 0.55, and 0.545 (18), which would result in C_E/C_P less than zero. Hence, for these compounds, C_E/C_P is fixed at zero, indicating very limited accumulation of these compounds in the erythrocyte. $R_{B/P}$ of olmesartan is not reported, however the compound does not penetrate red blood cells (29), hence C_E/C_P is also fixed at zero. For telmisartan, C_E/C_P is reported to be 0.5 (30), and assumed to be constant and independent of disease conditions.

Tissue to plasma partition coefficient. The tissue to plasma partition coefficients (Kp) for non-liver tissues are calculated using *in silico* method reported previously (31) under different disease conditions. In the Kp calculation, $f_{u,p}$ and $R_{B/P}$ values are calculated above, pKa and $logD_{7.4}$ values are in Table 1. For telmisartan, Kp values are derived from human positron emission tomography (PET) data (24) due to known mis-prediction made by *in silico* methods.

Blood flow. Tissue blood flows are modeled as fractions of cardiac output. The cardiac output, portal vein, splenic vein, and liver arterial blood flow under liver cirrhosis conditions are adjusted using values given in Table 3. Blood flows in other tissues are also adjusted accordingly such that the sum of blood flow fractions contributed by the tissues is 1.

Renal clearance. Renal clearance (CL_R) of prodrug of olmesartan (olmesartan medoxomil) under healthy and cirrhosis conditions has been reported (29). Since CL_R has not been reported for olmesartan, we assume that CL_R values of olmesartan and its prodrug are the same considering the fast conversion from prodrug to olmesartan in the human body (29). There is no reported CL_R of valsartan under conditions of cirrhosis but only for healthy individuals (32), hence the ratios of valsartan CL_R between healthy and cirrhotic conditions are estimated as the weighted mean values of rosuvastatin and olmesartan (0.85 and 0.79 for CP-A and B groups, Supplemental Materials) (11, 29). Alternatively, assuming changes in CL_R in cirrhosis are similar to those for ~~is proportional to~~ glomerular filtration rate (GFR) ~~and kidney transporters are not affect by cirrhosis~~, valsartan CL_R ~~under cirrhotic conditions~~ can be predicted using ratios for GFR changes in the previous meta-analysis (0.70 and 0.58 for CP-A and B in (5)). However, such approach leads to greater changes ~~o~~in CL_R than ~~the~~ observed ~~values in~~for rosuvastatin and olmesartan ~~studies~~ (11, 29). The pharmacokinetics of rosuvastatin in healthy (11) and liver cirrhosis individuals (11) have been published, however under cirrhotic conditions ~~only~~ derived pharmacokinetic parameters but not concentration-time course are reported. As such, rosuvastatin is not included in this study, because of the additional challenge in estimating absorption and hepatic clearance without time course data. We assume there is no renal excretion for the other three compounds (18, 24). The unbound renal clearance ($CL_{R,u}$) is calculated using reported or estimated clinical renal clearance assuming well-stirred conditions as described before (18):

$$CL_{R,u} = \frac{CL_R / R_{B/P}}{\dfrac{f_{u,p}}{R_{B/P}} \times \left[1 - \dfrac{CL_R / R_{B/P}}{Q_{renal,blood}} \right]} \tag{7}$$

where $Q_{renal,blood}$ is renal blood flow.

Hepatic clearance. CL_{pass} and CL_{act} of bosentan, repaglinide, and valsartan, CL_{met} of bosentan and repaglinide, as well as CL_{bile} of olmesartan and valsartan, for healthy individuals are estimated by fitting the model to the observed plasma concentration time profiles after intravenous dosing (11, 13, 15, 32). CL_{met} of olmesartan and valsartan, and CL_{bile} of repaglinide are fixed at zero (19, 29). CL_{bile} of bosentan is fixed at a previously predicted value using sandwich-cultured human hepatocyte (SCHH) (19). If we simultaneously estimate CL_{pass}, CL_{act}, CL_{met} (or CL_{bile}) by fitting the clinical data for each compound individually, the model may be over-parameterized as described before (17), leading to unreliable estimates. On the other hand, if we fix CL_{pass}, CL_{act}, CL_{met}, and CL_{bile} at SCHH predicted values given in a previous study (19), there are substantial discrepancies between simulations and data for some compounds. We want to minimize such discrepancies, since the following simulations and predictions for cirrhotic patients rely on the accuracy of simulation for healthy individuals. To address these issues, CL_{pass}, CL_{act}, CL_{met}, and CL_{bile} are estimated by fitting plasma concentration time profiles of each compound individually, however, they are bounded by their confidence intervals obtained in the previous study (i.e. *in vitro* SCHH (or human liver microsome, HLM) clearance × physiological scaling factor × confidence intervals of empirical scaling factors, where a unique set of empirical scaling factors and their confidence intervals are estimated by simultaneously leveraging data for multiple compounds). The details of the estimation of the confidence intervals are given in the original publication) (19). CL_{pass}, CL_{act}, CL_{met}, and CL_{bile} used for telmisartan prediction under healthy conditions are fixed at values given in the previous study due to the good agreement between data (30) and simulations (24). There is no published SCHH data of olmesartan, hence its CL_{pass}, CL_{act}, and CL_{bile} are estimated by fitting observed plasma concentration time course

(29) without boundaries based on SCHH ~~study~~. To assess the variability of the estimates, confidence intervals for CL_{pass}, CL_{act}, and CL_{bile} are approximated by using a residual bootstrap method as described before (19). Bootstrap is not performed for other compounds because their fitting has been bounded by confidence intervals generated ~~before~~previously.

Passive permeability of the compound is assumed be independent of the disease status, hence CL_{pass} under cirrhosis condition is assumed to be only affected by the functional liver mass.

$$CL_{pass,cirrhosis} = CL_{pass,healthy} \cdot R_{liver\ mass} \tag{8}$$

where $R_{liver\ mass}$ is the fraction of the functional liver size in healthy control.

CL_{met} under liver cirrhosis conditions is assumed to be decreased due to both reduced functional liver mass and the reduced metabolic enzyme activity as described previously (4, 5).

$$CL_{met,cirrhosis} = CL_{met,healthy} \cdot R_{liver\ mass} \cdot \sum_{i=1}^{n} \left(F_{enzyme,i} \cdot R_{metabolism,i} \right) \tag{9}$$

where F_{enzyme} is the fraction of the total metabolism contributed by each metabolic enzyme involved in the hepatic metabolism; $R_{metabolism}$ is the ratio of metabolic enzyme activity between the diseased group and the healthy control, i represents each metabolic enzyme, and n is the number of metabolic enzymes. According to previous HLM studies, 60% of dosed bosentan is metabolized through CYP3A4, and the remaining 40% metabolized through CYP2C9 (33), while 63% of repaglinide is metabolized by CYP2C8, 18% by CYP3A4, and 19% by UDP-glucuronosyltransferase (UGT) (34). Telmisartan is metabolized exclusively by UGT (35). We used reported $R_{metabolism}$ of CYP3A4, CYP2C8 and CYP2C9 activity in CP-A, CP-B, and CP-C

12

patients (5). The UGT activity is assumed to be not affected by liver cirrhosis as suggested by a previous study (36).

Similar to CL_{met}, in this study CL_{act} and CL_{bile} are assumed to depend on both functional liver mass and the transporter activity.

$$CL_{act,cirrhosis} = CL_{act,healthy} \cdot R_{liver\ mass} \cdot \sum_{i=1}^{n} \left(F_{active\ transporter,i} \cdot R_{active\ transporter,i} \right)$$
$$CL_{bile,cirrhosis} = CL_{bile,healthy} \cdot R_{liver\ mass} \cdot \sum_{i=1}^{n} \left(F_{biliary\ transporter,i} \cdot R_{biliary\ transporter,i} \right)$$
(10)

where $F_{transporter}$ is the fraction of each transporter made to CL_{act} (or CL_{bile}), and $R_{transporter}$ is the ratio of transporter activity between the diseased group and the healthy control. $R_{transporter}$ has been reported using mRNA measurements but the diseased individuals were not assessed based on Child-Pugh classification system (Table 3) (37, 38), hence in the prospective predictions (Method 1), we assume the three disease groups have the same $R_{transporter}$ and standard deviation. $F_{transporter}$ has been reported for olmesartan (OATP1B1, 0.53; OATP1B3, 0.47; no OATP2B1 and NTCP uptake (39, 40)) but not for the other four compounds, hence for other compounds $F_{transporter}$ are generated randomly from a uniform distribution.

Assuming liver cirrhosis has a ~~unique~~ similar impact on all uptake ~~(or biliary efflux)~~ transporters, $R_{transporter}$ values of CP-A and CP-B are estimated by fitting observed concentration-time courses of patients while fixing other parameters at their mean values in Table 3 (Method 2). Because the current simulations are not sensitive to CL_{bile} as they are to CL_{act} (Table 2), a similar assumption is also made on biliary transporters, although this assumption is not entirely consistent with mRNA data (Table 3). The uncertainty of fitted parameters are approximated by residual bootstrap (19). The pharmacokinetics of repaglinide ~~were was~~were reported as the average value of 9 CP-B and 3 CP-C patients (9). Studies for the other four compounds did not include CP-C

individual$\underline{s}$. We assumed $R_{transporter}$ of CP-C patients has the same value as that of CP-B patients, because adding separated parameters for CP-C patients does not improve the fitting (data not shown).

The previously reported fractions unbound in liver tissue ($f_{u,liver}$) (19, 24) are used for healthy individuals and the two cirrhosis groups, assuming $f_{u,liver}$ is not affected by the liver cirrhosis. Since there is no published value of $f_{u,liver}$ for olmesartan, it is predicted from $f_{u,p}$ as described previously (18).

Drug absorption. The absorption parameters k_a (or V_{max}, K_m) and F_a are estimated by fitting the observed plasma concentration-time profiles following oral dosing from healthy individuals in the liver cirrhosis studies (8-12), simultaneously with CL_{pass}, CL_{act}, CL_{met}, and CL_{bile} estimation by fitting intravenous data from healthy individuals as described above (with the exception of telmisartan fitting, where all parameters except for k_a and F_a are fixed as described above). Due to the lack of intestinal transporter data under cirrhotic conditions at this time, ~~Assuming~~ assuming liver is the major disposition organ, and no change of the intestinal transporter activity, the absorption parameters are kept the same for healthy and liver cirrhosis groups. Absorption parameters are not estimated for olmesartan, because the human pharmacokinetic study including individuals with cirrhosis was performed following intravenous bolus dosing (29).

Simulations of pharmacokinetics under liver cirrhotic conditions

Assuming all parameters are independent of each other and follow normal distributions, the values of albumin concentrations as the fraction of healthy control are randomly generated from a normal distribution with mean and standard deviation in Table 3, ~~so~~ as are values of other

14

parameters with relatively high sensitivity coefficients including ~~HTC~~ HCT values, cardiac output, portal vein blood flow, splenic vein blood flow, liver arterial blood flow, functional liver size, and hepatic transporter activity. For a few parameters with standard deviations of a similar magnitude as the mean values, ~~occasionally~~ negative values may be generated occasionally but were discarded. With generated parameter values, concentration-time profiles are simulated using the PBPK model.

RESULTS

Published plasma time course data in healthy individuals and cirrhotic patients for liver transporter substrates bosentan (12, 13), olmesartan (29), repaglinide (9, 15), and telmisartan (10, 30), valsartan (8, 32) were analyzed. The values of compound-specific parameters for healthy individuals are given in Table 1 (except for tissue-plasma partition coefficients (Kp) for non-liver tissues, shown in the Supplemental Materials). With fitted hepatic clearances and oral absorption parameters, the simulated bosentan, olmesartan, repaglinide, telmisartan, and valsartan plasma concentrations can reasonably match the observations from healthy individuals (Figure 1).

The local sensitivity analysis (Table 2) indicates that AUC_{plasma} is in general sensitive to parameters including plasma fraction unbound ($f_{u,p}$), blood to plasma ratio ($R_{B/P}$), hepatic active uptake (CL_{act}), passive diffusion (CL_{pass}), metabolic (CL_{met}) (or biliary (CL_{bile})) clearances, the functional liver tissue volume (V_{lt}), liver venous blood flow (Q_{hv}), cardiac output, and fraction absorbed (F_a). These results are consistent with published findings (18, 24). The AUC_{liver} of most compounds is sensitive to liver tissue fraction unbound ($f_{u,liver}$), CL_{met} (or CL_{bile}), V_{lt}, and F_a (Table 2).

To prospectively predict pharmacokinetics under liver cirrhosis conditions, the~~se~~ parameters with high sensitivity coefficients are adjusted. The ratios (and the standard deviations of ratios) between healthy individuals and liver cirrhosis patients (CP-A, CP-B, and CP-C) are estimated from published studies (Table 3). We used published mRNA data (37, 38) to estimate the ratios of transporter activities ($R_{transporter}$) between healthy individuals and ~~CP-A (and CP-B)~~diseased groups (Method 1). Unfortunately, these data are not classified based on Child-Pugh system so~~.~~ ~~As such, for liver transporter activity,~~ the same ratio is applied to ~~different~~ all cirrhotic groups

16

(Table 3). The parameter values under cirrhosis are predicted as the products of healthy values (Table 1) and the ratios (Table 3). The fraction each transporter contributes to hepatic uptake or biliary efflux is unknown except for olmesartan uptake (39, 40), hence is randomly generated in the simulations. Assuming parameters are independent of each other and follow normal distributions with means and standard deviations given in Table 3, 1000 simulated plasma concentration-time profiles are generated for each compound. The averaged simulations for liver cirrhosis patients, 2.5 and 97.5 percentiles are superimposed on the observations (Figure 2). The observed and predicted AUC_{plasma} with 95% prediction intervals are reported in Table 4.

The predictions more reasonably match observations from CP-A groups than CP-B groups. This is probably due to mis-prediction of liver transporter activity under CP-B conditions using mRNA data.

Assuming in liver cirrhosis has the same impact on all uptake (or efflux) transporters are similarly affected within a grade but differences exist between grades, we estimated $R_{transporter}$ by simultaneously fitting observed pharmacokinetics of the five compounds (Method 2) (Table 3). Fitted values of $R_{transporter}$ for uptake transporters in CP-A groups are similar to the values estimated using published mRNA data, however, fitted values for CP-B groups are different from mRNA-estimated values. With the fitted $R_{transporter}$, the overall agreement between simulations and observations is improved (Figure 3) as are predictions for AUC_{plasma} (Table 4).

17

DISCUSSION

We established a PBPK model to simulate how liver cirrhosis affects the pharmacokinetics of liver transporter substrates. A major challenge is that the effect of liver cirrhosis on the *in vivo* transporter activity is unknown. Although previous studies have reported that liver cirrhosis may change mRNA and protein expression levels (37, 38), it is unclear whether changes in transporter ~~mRNA or protein~~ expression levels due to liver disease can be directly translated into pharmacokinetics in patients.

We initially prospectively predicted the change of *in vivo* liver transporter activity ($R_{transporter}$) using mRNA data. ~~Generally t~~The mean predictions can more reasonably match mean observations from CP-A than CP-B groups. This might arise if more mRNA samples in these studies were taken from CP-A patients (37, 38). To improve prediction accuracy, transporter mRNA or protein expression data classified using the Child-Pugh system would be highly desirable in future. In addition, because the fractional contributions that transporters made to the total uptake are unknown, they are randomly generated in this analysis. This leads to additional uncertainty in predictions. Several different *in vitro* assays have been developed to deconvolute the contribution made by individual transporters to the overall uptake (17). It could be useful to incorporate these data into the model once they are available. The $R_{transporter}$ value may also be predicted using experimentally determined protein expression levels, but would be only slightly less than the value estimated from mRNA data (37). ~~None of these compounds has been reported to be NTCP substrates, hence we did not use NTCP mRNA data.~~ In this model, because we assumed that all parameters in Table 1 follow normal distributions and are independent with each other, the variability of the simulations may be over-predicted. However, ~~such an assumption is~~

~~validated by the fact that~~ the approximated variability is in general comparable to the observed variability (Table 4 and Fig. 2).

To better describe the data, we re-estimated ~~individual~~ $R_{transporter}$ for CP-A and CP-B groups by fitting the observed pharmacokinetics and assuming all uptake transporters are similarly affected in the diseased conditions. As expected, the fitted value ~~of~~ for CP-A groups (0.78) ~~but not CP-B groups (0.31)~~ is similar to the mRNA-predicted values for uptake transporters (0.65 for OATP1B1, 0.73 for OATP1B3, and 0.77 for OATP2B1~~.~~), however the fitted value for CP-B groups (0.31) is lower than the~~se~~ ~~reported~~ mRNA-predicted values. Thi~~se~~ top-down fitting approach provides an alternative ~~approach~~ method ~~to estimated $R_{transporter}$ additional~~ to the mRNA-predicted $R_{transporter}$. The advantage of top-down approach is to characterize the impact of cirrhosis on the transporter activity based on the CP system, which is not available from current mRNA data. The two approaches should be further tested when data ~~of~~for more compounds are available. We assumed that differences were due to liver transporter parameters, but given the very similar results with IV olmesartan and ~~the~~ ~~due to the~~ a lack of data on intestinal changes, we cannot rule out as ~~the~~an alternative hypothesis ~~given the very similar results with IV olmesartan~~ that ~~may be the~~absorption is affected to varying degrees in the diseased patients. ~~Since the fitted $R_{transporter}$ can better describe the in vivo data than the mRNA-predicted $R_{transporter}$, the fitted $R_{transporter}$ would be preferable in predicting pharmacokinetics of other compounds under cirrhosis conditions.~~

Additionally, liver cirrhosis has a pronounced impact on the observed pharmacokinetics of some compounds (e.g. valsartan) but not others (e.g. olmesartan), which makes it challenging to use a unique $R_{transporter}$ value to describe the change in the pharmacokinetics of all the compounds. It may be that the Child-Pugh score is not an accurate enough indicator of hepatic function,

considering the score is not directly assessed on liver function. For example, a large body of conflicting literature on changes in hepatic blood flows in cirrhosis have been generated based on Child-Pugh classification (5), indicating that given the current techniques, the Child-Pugh score cannot properly reflect the physiological changes due to cirrhosis. On the other hand, although not reflected in the mRNA data, it is also possible that the disease can more significantly affect the activity of some transporters than others. As such, because the contribution each transporter makes to the total hepatic uptake are different varies for different compounds, the liver cirrhosis cwould also have different impacts on these compounds. To test this hypothesis, we assumed that there are type-1 and type-2 uptake transporters responsible for the hepatic uptake of these compounds that have different $R_{transporter}$ values, and estimated parameters by fitting the clinical observations. With such approach, the mean simulations have improved agreement with the observations (data not shown); however, except for valsartan, the improvement is not significant. Furthermore, such an approach is hard to apply as a prospective prediction because of the lack of information about the contributions of each transporter made to the total uptake.

In conclusion, a PBPK model for liver transporter substrates to simulate pharmacokinetics under liver cirrhosis conditions wasis established, and a meta-analysis wasis performed to obtain system dependent parameters. This model can be useful in understanding the changes of in the liver transporter activity due to cirrhosis, and may aid predicting systemic and potentially liver exposure of the liver transporter substrates under cirrhotic conditions in future.

ACKNOWLEDGMENTS

HIGHLIGHTS

What is the current knowledge on the topic?

PBPK models have been developed to simulate pharmacokinetics of liver transporter substrates and more permeable compounds in healthy individuals. Previously developed PBPK models for individuals with liver cirrhosis assume well-stirred conditions in the liver, hence cannot be reasonably expected to describe the pharmacokinetics of transporter substrates.

What question did this study address?

This study aims at characterizing a PBPK model capable of ~~predicting~~ simulating the pharmacokinetics of liver transporter substrates under cirrhotic conditions, by incorporating changes in physiological and biological parameter values.

What this study adds to our knowledge?

This study presents the first mechanistic model to estimate the impact of liver cirrhosis on human pharmacokinetics of liver transporter substrates.

How this might change clinical pharmacology and therapeutics?

This model can be useful in understanding the changes in liver transporter activity due to cirrhosis, and may aid in predicting systemic and liver exposure for liver transporter substrates under cirrhotic conditions. It can be useful in the design of clinical trials and ultimately for dose adjustments in clinical practice for cirrhotic patients in the future.

REFERENCE

(1)   Schuppan, D. & Afdhal, N.H. Liver cirrhosis. *Lancet* **371**, 838-51 (2008).

(2)   Rodighiero, V. Effects of liver disease on pharmacokinetics. An update. *Clinical pharmacokinetics* **37**, 399-431 (1999).

(3)   Jones, H. & Rowland-Yeo, K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. *CPT: pharmacometrics & systems pharmacology* **2**, e63 (2013).

(4)   Edginton, A.N. & Willmann, S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. *Clinical pharmacokinetics* **47**, 743-52 (2008).

(5)   Johnson, T.N., Boussery, K., Rowland-Yeo, K., Tucker, G.T. & Rostami-Hodjegan, A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. *Clinical pharmacokinetics* **49**, 189-206 (2010).

(6)   Strougo, A., Yassen, A., Krauwinkel, W., Danhof, M. & Freijer, J. A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditions. *Drug metabolism and disposition: the biological fate of chemicals* **39**, 1278-87 (2011).

(7)   Wilkinson, G.R. & Shand, D.G. Commentary: a physiological approach to hepatic drug clearance. *Clinical pharmacology and therapeutics* **18**, 377-90 (1975).

(8)   Brookman, L.J. *et al.* Pharmacokinetics of valsartan in patients with liver disease. *Clinical pharmacology and therapeutics* **62**, 272-8 (1997).

(9)   Hatorp, V., Walther, K.H., Christensen, M.S. & Haug-Pihale, G. Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease. *Journal of clinical pharmacology* **40**, 142-52 (2000).

(10)   Stangier, J., Su, C.A., Schondorfer, G. & Roth, W. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. *Journal of clinical pharmacology* **40**, 1355-64 (2000).

(11)   Simonson, S.G., Martin, P.D., Mitchell, P., Schneck, D.W., Lasseter, K.C. & Warwick, M.J. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. *European journal of clinical pharmacology* **58**, 669-75 (2003).

(12)   van Giersbergen, P.L., Popescu, G., Bodin, F. & Dingemanse, J. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. *Journal of clinical pharmacology* **43**, 15-22 (2003).

(13)   Weber, C. *et al.* Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. *Clinical pharmacology and therapeutics* **60**, 124-37 (1996).

(14)   Auletta, M., Oliviero, U., Iasiuolo, L., Scherillo, G. & Antoniello, S. Pulmonary hypertension associated with liver cirrhosis: an echocardiographic study. *Angiology* **51**, 1013-20 (2000).

(15)   Hatorp, V., Oliver, S. & Su, C.A. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. *International journal of clinical pharmacology and therapeutics* **36**, 636-41 (1998).

(16)   Tolman, K.G., Fonseca, V., Dalpiaz, A. & Tan, M.H. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. *Diabetes care* **30**, 734-43 (2007).

(17) Li, R., Barton, H. & Varma, M. Prediction of Pharmacokinetics and Drug–Drug Interactions When Hepatic Transporters are Involved. *Clinical pharmacokinetics*, 1-20 (2014).

(18) Jones, H.M. *et al.* Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. *Drug metabolism and disposition: the biological fate of chemicals* **40**, 1007-17 (2012).

(19) Li, R. *et al.* A "middle-out" approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling. *Journal of pharmacokinetics and pharmacodynamics* **41**, 197-209 (2014).

(20) Poirier, A., Cascais, A.C., Funk, C. & Lave, T. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. *Journal of pharmacokinetics and pharmacodynamics* **36**, 585-611 (2009).

(21) Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y. & Sugiyama, Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. *The Journal of pharmacology and experimental therapeutics* **328**, 652-62 (2009).

(22) Pfeifer, N.D., Bridges, A.S., Ferslew, B.C., Hardwick, R.N. & Brouwer, K.L. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver. *The Journal of pharmacology and experimental therapeutics* **347**, 737-45 (2013).

(23) Pfeifer, N.D., Yang, K. & Brouwer, K.L. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. *The Journal of pharmacology and experimental therapeutics* **347**, 727-36 (2013).

(24) Li, R., Ghosh, A., Maurer, T.S., Kimoto, E. & Barton, H.A. Physiologically Based Pharmacokinetic Prediction of Telmisartan in Human. *Drug metabolism and disposition: the biological fate of chemicals*, (2014).

(25) Holford, N.H., Ambros, R.J. & Stoeckel, K. Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. *Journal of pharmacokinetics and biopharmaceutics* **20**, 421-42 (1992).

(26) Hedges, L.V. Meta-Analysis. *Journal of Educational and Behavioral Statistics* **17**, 279-96 (1992).

(27) Killeen, P.R. An alternative to null-hypothesis significance tests. *Psychological science* **16**, 345-53 (2005).

(28) Kalvass, J.C. & Maurer, T.S. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. *Biopharmaceutics & drug disposition* **23**, 327-38 (2002).

(29) U.S. Food and Drug Administration & Center for Drug Evaluation and Research. Benicar NDA 21-286 Clinical Pharmacology Biopharmaceutics Review. (2002).

(30) Stangier, J. *et al.* Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. *Journal of clinical pharmacology* **40**, 1312-22 (2000).

(31)   Rodgers, T. & Rowland, M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. *Journal of pharmaceutical sciences* **95**, 1238-57 (2006).

(32)   Flesch, G., Muller, P. & Lloyd, P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. *European journal of clinical pharmacology* **52**, 115-20 (1997).

(33)   Dingemanse, J. & van Giersbergen, P.L. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. *Clinical pharmacokinetics* **43**, 1089-115 (2004).

(34)   Sall, C., Houston, J.B. & Galetin, A. A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. *Drug metabolism and disposition: the biological fate of chemicals* **40**, 1279-89 (2012).

(35)   Wienen, W. *et al.* A Review on Telmisartan: A Novel, Long-Acting Angiotensin II-Receptor Antagonist. *Cardiovascular Drug Reviews* **18**, 127-54 (2000).

(36)   Strassburg, C.P. *et al.* Developmental aspects of human hepatic drug glucuronidation in young children and adults. *Gut* **50**, 259-65 (2002).

(37)   Zollner, G. *et al.* Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. *Journal of hepatology* **38**, 717-27 (2003).

(38)   Ogasawara, K. *et al.* Hepatitis C Virus-related Cirrhosis is a Major Determinant of the Expression Levels of Hepatic Drug Transporters. *Drug Metabolism and Pharmacokinetics* **25**, 190-9 (2010).

(39)   Yamada, A. *et al.* Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. *Drug metabolism and disposition: the biological fate of chemicals* **35**, 2166-76 (2007).

(40)   Nakagomi-Hagihara, R. *et al.* OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. *Drug metabolism and disposition: the biological fate of chemicals* **34**, 862-9 (2006).

FIGURE LEGENDS

Figure 1. The observed and simulated mean plasma concentration time profiles in healthy individuals of (A) bosentan (10 mg 5 min intravenous infusion and 125 mg oral dosing), (B) olmesartan (8 mg intravenous bolus dosing), (C) repaglinide (2 mg 15 min intravenous infusion and 4 mg oral dosing), (D) telmisartan (40 mg 20 min intravenous infusion and 40 mg oral dosing), and (E) valsartan (20 mg intravenous bolus and 160 mg oral dosing). The blue circles and solid lines represent the observations and simulations following intravenous dosing. The red squares and dashed lines represent the observations and simulations following oral dosing. The simulations are performed with parameter values for healthy individuals given in Table 1.

Figure 2. The observed and predicted plasma concentration time profiles of (A) bosentan, (B) olmesartan, (C) repaglinide, (D) telmisartan, and (E) valsartan. The blue, red, and black represent the healthy individuals, patients with ~~Grade~~ CP-A liver cirrhosis, and the patients with ~~Grade~~ CP-B liver cirrhosis, respectively. The markers (i.e., squares, circles, and triangles) represent the observations. The solid and dotted lines represent the average and 95% prediction intervals (approximated by 2.5 and 97.5 percentile) of 1000 simulations where means and standard deviations of mRNA-derived $R_{transporter}$ (Method 1) and other parameters (Table 3) are used to generate random values. Error bars indicate 95% prediction intervals estimated using observed standard deviations.

Figure 3. The observed and simulated plasma concentration time profiles of (A) bosentan, (B) olmesartan, (C) repaglinide, (D) telmisartan, and (E) valsartan. The blue, red, and black represent the healthy individuals, patients with CP-A liver cirrhosis, and the patients with CP-B liver cirrhosis, respectively. The markers (i.e., squares, circles, and triangles) represent the observations. The solid lines represent the simulations assuming all uptake transporters are equally affected by the liver cirrhosis conditions and $R_{transporter}$ is fitted (Method 2). All simulations assume the biliary efflux transporters are equally affected by the liver cirrhosis, and the impact of cirrhosis on all transporters depends on Child-Pugh scores. Error bars indicate 95% prediction intervals estimated using observed standard deviations.